Skip to main content
OncoPrescribe
  • HOME
  • WHY US
  • ABOUT
  • SIGN IN
  • SIGN UP

Top Ad

hem-onc-updates

Advertisement

KEYTRUDA® (Pembrolizumab)

July 2, 2020July 2, 2020 RR FDA Approvals
Non-Melanomatous Skin Cancers

The FDA on June 24, 2020 approved KEYTRUDA® for patients with recurrent or metastatic cutaneous Squamous Cell Carcinoma (cSCC) that is not curable by surgery or radiation. KEYTRUDA® is a product of Merck & Co., Inc.

Related Posts:

  • KEYTRUDA® (Pembrolizumab)
  • KEYTRUDA® (Pembrolizumab)
  • KEYTRUDA® (Pembrolizumab)
  • KEYTRUDA® (Pembrolizumab)
  • KEYTRUDA® (Pembrolizumab)
  • KEYTRUDA® (Pembrolizumab)

Post navigation

XPOVIO® (Selinexor)
PHESGO®

Bottom Ad

hem-onc-updates

Advertisement

Subscribe

Subscribe

Ad 1

OncoPrescribe-Ad

Advertisement

Ad 2

OncoPrescribe-CDC

Advertisement

Ad 3

Advertisement

Ad 4

OncoPrescribe

Advertisement

  • PRIVACY
  • TERMS
  • DISCLAIMER
  • CONTACT
OncoPrescribe, LLC. All Rights Reserved